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Malaria is devastating disease and global public health problem, with nearly half world population 
exposed to risk. Illness is caused by five Plasmodium species, P. falciparum, P. ovale, P. vivax, P. malaria 
and P. knowlesi, from which P. falciparum is the most serious one causing cerebral malaria and is the major 
reason for malaria mortality. Vaccine against malaria is not expected in the near future and chemotherapy 
remains as most feasible alternative for treatment of the disease. The development of widespread drug-
resistance to chloroquine (CQ), the most successful antimalarial drug up to date, has resulted in severe 
health issues for countries in malaria endemic regions. Organic peroxides, like artemisinins, 1,2,4-triox-
anes, 1,2,4-trioxolanes, 1,2,4,5-tetraoxanes and their chimeras, are the best choice for malaria treatment 
nowadays. These therapeutics are fast acting, non-toxic, low costing and without reported data of parasite 
resistance. Stability of peroxide bonds enables synthetic comfort and resulting in diversity of synthesized 
structures. The most important classes of peroxide antimalarials with promising representatives are re-
viewed and possible mechanisms of action were presented in details. 
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АРТЕМИСИНИ И СИНТЕТИЧКИ ПЕРОКСИДИ КАКО МНОГУ ЕФИКАСНИ 
АНТИМАЛАРИЦИ
Маларијата е многу тежок светски проблем на јавното здравство, бидејќи околу половина од 
свтетската популација е изложена на ова заболување. Болеста е предизвикана од пет видови Plas-
modium, P. falciparum, P. ovale, P. vivax, P. malariа и P. knowlesi, од кои најопасен е P. falciparum кој 
предизвикува церебрална маларија и е главна причина за смртноста кај маларијата. Вакцина против 
маларија не се очекува во блиска иднина и хемотерапијата останува единствена практична алтерна-
тива во лекувањето и третирањето на болеста. Развивањето на сѐ поголемата резистентност на лекот 
хлорохин (CQ), досега најуспешен познат лек против маларија, доведува до сериозни здравствени 
проблеми во државите со области на ендемска појава на маларија. Органските пероксиди-артеми-
сини, 1,2,4-триоксани, 1,2,4-триоксолани, 1,2,4,5-тетраоксани и нивните разновидни форми, во де-
нешно време се најдобар избор за третирање на маларијата. Овие терапевтици имаат брзо дејство, 
нетоксични се, евтини и не е позната резистентност на паразитот спрема нив. Стабилноста на нив-
ните пероксидни врски овозможува синтетизирање и добивање разновидни синтетички форми. Во 
прилогов подетално се дискутирани најважните класи и најпогодните претставници на пероксидни 
антималарици, како и можниот механизам на нивното дејство.
Клучни зборови: антималарици; артемисинин; пероксиди; триоксани; триоксолани; 
тетраоксани; химери
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1. INTRODUCTION
Malaria is a massive global public health 
problem in more than 100 countries, inhabited 
by some 40% of the world’s population, with 
300–500 million clinical cases and over one 
million deaths each year [1]. Every 30 seconds 
a child somewhere dies of malaria. In any given 
year, nearly 10% of the global population will 
suffer a case of malaria, and more then half of 
the cases are caused by Plasmodium falciparum 
and the rest are caused by Plasmodium vivax 
[2]. While a vaccine against malaria continues 
to be elusive [3], chemotherapy remains the 
most viable alternative towards treatment of the 
disease. During last few years the situation has 
become urgent in many ways, but mainly be-
cause the malaria parasite has developed multi-
ple drug resistance (MDR) to most used drugs, 
such as quinine, chloroquine (CQ), mefloquine 
(MFQ), primaquine, and others. The resistance 
is most serious with CQ, the most widely and 
cheapest drug used in treatment, because of the 
development of CQ-resistant (CQR) strains of 
P. falciparum (P.f.) – Indochina W2, Brazil 
IEC-306, FCR3, and K1. Combating malaria is 
even more complex because of the contempo-
rary development of resistance by the mosquito 
vector to currently used insecticides [4]. For 
the reasons indicated above, the World Health 
Organization (WHO) has designated malaria as 
a major health problem that urgently needs the 
mobilisation of scientific, industrial, and politi-
cal communities [5].
Artemisinin (ART, 1), the active principle 
of plant Artemisia annua L., due to its high ac-
tivity against CQR strains [6], opened new pos-
sibilities for combating this pestilence. Since 
the early 1980’s hundreds of semisynthetic and 
synthetic peroxides were developed and tested 
for their antimalarial activity results, which 
have been extensively reviewed [7, 8, 9]. The 
therapeutic significance of this drug class lies 
in its noticeable lack of parasite resistance and 
absence of toxicity during patient treatment. 
The only evidence of in vitro resistance was 
found in French Guiana [10] and the Thailand-
Cambodia border area, where certain ART de-
rivatives were used in uncontrolled and illegal 
self-medication. 
This review summarizes recent achieve-
ments in the area of peroxide drug development 
for malaria chemotherapy. 
2. THE LIFE CYCLE OF THE MALARIA 
PARASITE
Protozoa of the genus Plasmodium cause 
malaria. Four species of Plasmodium cause the 
disease in humans, P. falciparum, P. malaria, P. 
ovale and P. vivax. Of these, P. falciparum may 
cause the condition known as cerebral malaria, 
and is responsible for the majority of fatal out-
comes.
The pathogenesis [11] and life cycle of 
the malaria parasite is complex [12] and con-
sists of two stages: the sexual stage (sporogo-
ny), which takes place within the mosquito, and 
the asexual stage (schizogony), which takes 
place in the host [7c, 13]. The illness is started 
when the infected female mosquito of the genus 
Anopheles feeds on the blood of the uninfected 
vertebrate host. In less than one hour sporo-
zoites travel to the liver, invade hepatocytes, 
and undergo exoerythrocytic schizogony. After 
some time, depending on the plasmodium spe-
cies, the schizonts transforms into merozoites, 
which after being released into the blood stream 
invade erythrocytes. After significant reorgani-
zation of membrane proteins of the occupied 
erythrocyte [12e], merozoites undergo erythro-
cytic schizogony, which comprises young rings 
(12h after erythrocyte infection), mature rings 
(18h), early trophozoites (24h), mature tropho-
zoites (30h), early schizonts (36h) and mature 
schizonts (42h). At the end of erythrocytic 
schizogony, parasites return into merozoite 
form, but enormously multiplied causing splat-
tering of the host. Released merozoites invade 
new red blood cells and start a new erythrocytic 
schizogony cycle. Erythrocytic schizogony oc-
curs every 2–3 days, depending on Plasmodium 
species. Each cycle is accompanied by typical 
malaria symptoms such as fever, chills, head-
ache and exhaustion. After several cycles, some 
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of the merozoites undergo sexual development 
and transform into gametocytes. 
Gametocytes remain in the erythrocytes 
and are consumed by an anopheles mosquito. 
In the mosquito, female and male gameto-
cytes join and form a zygote. Within 18 to 24 
hours, the zygote transforms into a slowly mo-
tile ookinete. Between 7 and 15 days, depend-
ing on the Plasmodium species, and ambient 
temperature, a single oocyst forms more than 
10,000 sporozoites. The motile sporozoites mi-
grate into the salivary glands and accumulate 
in the acinar cells. When the infected mosquito 
bites a susceptible vertebrate host, a new par-
asite cycle starts. In Table 1 the length of the 
P. falciparum life cycle is presented.
T a b l e  1
Life cycle stages of P. falciparum with time lengt
1 Ookinete formation 24 to 48 hours
2 Oocyst maturation 9 days
Invasion of salivary 
glands (1+2)
10 days
3 Circulation of 
sporozoites in the 
blood stream
1 hour max.
4 Hepatic schizogony 6 days
5 Erythrocytic 
schizogony
48 hours
6 Gametocytogony 10 days
Complete cycle  
(1 to 6)
27 days
The malaria parasite has limited capacity 
for de novo amino acid synthesis, and its sur-
vival is dependent on haemoglobin proteolysis. 
The parasite digests haemoglobin in the food 
vacuole (FV), supplying itself with the amino 
acids necessary for nutrition, and liberates free 
haem [Fe(II)PPIX], which is subsequently oxi-
dized to haematin [Fe(III)PPIX]. Free haema-
tin can damage cellular metabolism by inhib-
iting enzymes, by peroxidation of membranes, 
and by producing the reactive oxygen species 
(ROS) in the acidic environment of the FV [14]. 
In order to protect itself the parasite eliminates 
haematin by sequestering it as hemozoin. He-
mozoin is a noncovalent aggregate of several 
units of haematin linked via coordinate bonds 
formed between the Fe(III) of one haematin and 
the carboxylate side chain of the adjacent one 
[15]. Hemozoin is insoluble, and accumulates 
in the lymphatic tissue, liver, bone marrow, and 
brain. It was found that haem [Fe(II)PPIX] can-
not polymerize to hemozoin and is an effective 
inhibitor of Fe(III)PPIX polymerization, even 
better so than CQ [16].
3. ARTEMISININ AND DERIVATIVES
The active ingredient of Artemisia an-
nua L. was identified as artemisinin 1 (ART, 
qinghaosu – QHS, Figure 1), a sesquiterpene 
lactone with the endoperoxide function [6]. 
The very same compound was also isolated 
in Belgrade by Professor Milutin Stefanović’s 
group in the early 1970’s, however, the wrong 
structure was proposed (Figure 1) [17]. The 
structure of ART was elucidated in 1979 by 
X-ray analysis, which was supported by total 
synthesis [18]. Since then, many total synthe-
ses have been achieved [19, 20], including the 
newest one by Hao and co-workers [21]. Fur-
thermore, large scale synthesis of ART was de-
veloped by continuous flow synthesis starting 
from artemisinic acid [22]. ART is an erythro-
cytic schizonticid and exhibits rapid activity 
against all types of human and most animal 
malaria. It is effective against both the CQS 
and CQR strains of P. falciparum [(IC50) D6 = 
9.0 nM, W2 = 6.7 nM, TM91C235 = 13.0 nM] 
[23], and has been successfully used for the 
treatment of severe cerebral malaria [7c]. ART 
has poor solubility in water and it is adminis-
trated as a water or oil suspension. Better re-
sults were achieved when it was administered 
intramuscularly (i.m.) as a suspension in oil 
than orally (p.o.) in water.
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Metabolites isolated after p.o. admin-
istration are devoid of peroxide function and 
have no antimalarial activity, strongly suggest-
ing that the peroxide function is a critical part 
of the pharmacophore. This was demonstrated 
by a complete lack of activity of derivative 2 
[24] (Figure 2). The high activity of deoxo de-
rivative 3 [25] reveals that lactone ring D is not 
required for activity, as was confirmed with a 
number of derivatives (vide infra). Similarly, 
tricyclic derivative 4 (vide infra), which is 
nearly as active as ART showed that ring A is 
also not required. On the other hand, the low 
activity of isostere 5 clearly shows the impor-
tance of the ketal moiety for good activity [26]. 
SAR of ARTs showed that the high complex-
ity of the structure is not necessary, and more 
important, further optimization and structural 
simplification is possible for activity improve-
ment. In addition, it was assumed that the good 
activity of ART was due, at least partially, to 
its amphiphilic structure, which facilitates cell 
membrane permeability.
Fig 1. Structure of artemisinin
Fig. 2. Structures of derivatives that illustrated SAR
3.1. First generation of artemisinin derivatives 
The first semisynthetic derivatives of 
ART were simple ethers (7), esters (8), and 
carbonates (9) of dihydroartemisinin (DHA, 6) 
(Scheme 1) [6, 7a]. The DHA lactol, which is 
easily obtained from 1, and is the first metabo-
lite of ART, is twice as active as ART but ex-
hibits a relatively high degree of neurotoxicity. 
DHA is effective against severe cerebral ma-
laria, but suffers from poor oral bioavailability, 
high recrudescence, and noteworthy is the re-
port on its neurotoxicity [27], especially when 
used in higher doses in continuity [28].
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Artemether 7a and arteether 7b were de-
signed to increase lipid solubility, PK profile 
and antimalarial activity in comparison to ART 
and DHA. Both are fast acting blood schizon-
ticides and are especially active against CQR 
strains. Administration in high doses can pro-
duce neurotoxic effects, probably due to its 
metabolitic conversion to DHA. Later, it was 
shown that neurotoxicity occurs when the com-
pounds are administered in at least five times 
higher doses than is recommended. Today, ar-
temether 7a is the most widely used derivative 
and is applied as oil solution for i.m. injection 
(Artenam®, Artemos®), or recently in combina-
tion with lumefantrine (Coartem®).
Although carbonates 9 exhibited higher 
in vivo activity then ART, DHA and 7, there is 
no reported clinical application, probably be-
cause of their low stability under physiological 
conditions, due to their fast hydrolysis to DHA.
For the treatment of severe forms of ma-
laria, water-soluble derivatives of ART (Figure 
3) are indispensable, such as sodium-artesunate 
8c and artelinic acid derivatives 10 [29]. The 
derivatives can be administered intravenously 
(i.v.), which enables faster and more efficacious 
antimalarial effects compared to less polar de-
rivatives that are administered i.m as an oil 
suspension. Artesunate 8c rapidly diminishes 
parasitemia and is very efficacious in the res-
toration to consciousness of comatose cerebral 
malaria patients [30]. Its shortcoming is high 
recrudescence of the disease and is normally 
used in ACT1 with MFQ [7e] and amodiaquine 
(Arsucam®). Na-artesunate is used as freshly 
prepared solution in dextrose or saline because 
of rapid hydrolysis to DHA.
Artelinic acids 10a possesses C(10) β-ether 
linkages and thus are hydrolytically more stable 
than artesunate 8c. The acid 10a expresses in vit-
ro activity comparable to ART and 8c against the 
D6 and W22 strains of P. falciparum, but shows 
superior in vivo activity against P. berghei [29].
Moreover, 10a has a longer plasma-life [29], 
higher plasma concentration, higher binding 
1 ACT – artemisinin combination therapy
2	 D6	(Sierra Leone strain)	is	resistant	to	mefloquine	and	susceptible	
to	chloroquine,	pyrimethamine	and	sulfadoxine;	W2	(Indochina 
strain)	is	resistant	to	chloroquine,	quinine,	pyrimethamine	and	
sulfadoxine,	and	susceptible	to	mefloquine.	
Scheme 1. Transformations of ART into first generation derivatives
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capacities, and lower toxicity in comparison to 
other first generation semisynthetic ART deriva-
tives [7c]. Although methyl ester 10c exhibits 
higher in vitro activity, it is less suitable because 
of its low solubility in water. Artelinic acid 10a 
was relatively well tolerated in rats; for example, 
50 mg kg–1 intramuscular doses of 10a given for 
7 consecutive days caused only mild anorectic 
toxicity. In one study [31], single intravenous 
dose LD
50
 values for 10a and artesunate 8c were 
120 and 350 mg kg–1, respectively. During neu-
rotoxicity tests 36 mg kg–1 intramuscular doses 
of 10a were administered for 7 consecutive days 
to rats, and no behavioral abnormalities or brain 
damage were detected [32]. However, recently 
[33], neuronal injury became evident when 160 
mg kg–1 of 10a was administered orally to rats 
for 9 consecutive days.
Recently, a new group of ether deriva-
tives 11 and 12 (Figure 4) were synthesized to 
examine the role of side chain elongation on 
antimalarial activity [34]. It was shown that 
elongation of the side chain increased activ-
ity, but not at the level of parent arteether 7b 
(Table 2). The most active derivatives were 11e 
and 11f, which exhibited 100% suppression 
under 6 mg kg–1 × 4 day doses. Derivative 11f 
was more active, with 100% suppression and 
5/6 cured mice under 6 mg kg–1 × 4 day doses. 
Interestingly, corresponding acids 12 were sig-
nificantly less active, similarly to artesunic acid 
8d being less active in comparison to 7b.
Fig. 3. Structures and antimalarial activities of derivatives 8a and 10
Fig. 4. Structures of derivatives 8d, 11 and 12
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T a b l e  2
Antimalarial activity of selected compounds 11 against multidrug resistant strain P. yoelii nigeriensis
 
Compound n mg kg–1 × 4 day
% suppression of parasitemia 
on day 4
Cured/Treated
11a 0
48
24
12
6
100
100
100
100
12/12
11/12
9/11
3/6
11b 1
48
24
12
6
3
100
100
100
100
98.3
5/5
5/5
9/11
6/12
0/6
11c 2
48
24
12
6
3
100
100
100
100
99.5
5/5
5/5
17/17
11/12
0/6
11d 3
48
24
12
6
100
100
100
100
5/5
5/5
5/5
1/5
11e 4
48
24
12
6
3
100
100
100
100
100
6/6
6/6
6/6
9/12
0/6
11f 6
48
24
12
6
100
100
100
100
6/6
6/6
6/6
5/6
7b
6
3
100
100
6/6
0/6
8d
48
24
100
100
6/6
0/5
First generation derivatives suffer from 
short plasma life and CNS toxicity caused by 
rapid metabolism into DHA [35]. Ethers 7 were 
metabolized by cytochrome P-450 forming 
C(α)-hydroxyl derivative 13, which was fur-
ther transformed into DHA (Scheme 2). Esters 
8 simply hydrolyze to DHA. In addition, all of 
these derivatives possess acetal or hemiacetal 
groups in the D ring, and therefore are readily 
hydrolyzed under acidic conditions after p.o. 
administration. The longer plasma half-life of 
artelinic acid 10a, most likely, is caused by ster-
ic hindrance and poorer accessibility to P-450. 
Consequently, second generation semisynthetic 
derivatives of ART were designed to overcome 
these disadvantages.
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3.2. Second generation of artemisinin 
derivatives
Suppression of metabolic transforma-
tions was attempted in several ways. One was 
modification of artelinic acid 10a by introduc-
ing substituents on the α-carbon (Figure 5) [35]. 
The compounds were more active against W2 
than against the D6 clone, and it was found that 
electronic effects, lipophilicity, and steric fac-
tors have considerable influence on antimalar-
ial activity. Configuration at the C(α) also con-
tributed to activity, i.e. (S)-isomers were more 
active than (R)-isomers. The most active com-
pound 14 was 10, 20 and 40 times more active 
then 7b, ART and 10a, respectively. 
Replacing the O-alkyl group with an 
O-phenyl group should prevent the oxidative 
dealkylation described in Scheme 2 (Figure 5) 
[36]. Derivative 15 was in vitro as active as ar-
temether, but had outstanding in vivo antimalar-
ial activity that was higher than clinically used 
sodium artesunate. Moreover, introducing a 
CF
3
-group metabolically stabilized the com-
pound compared to its parent compound (i.e., H 
instead of CF
3
).
Scheme 2. Metabolic transformations of derivatives 7 and 8
Fig. 5. Structures and antimalarial activities of derivatives 14–16
Introducing a lactam ring instead of lactone 
or acetal moieties also stabilized compounds un-
der physiological conditions. Many 11-azaartem-
isinins 16 (Figure 5) were described [37] and they 
exhibited significantly higher antimalarial activity. 
Moreover, the possibility of changing the substitu-
ents on the nitrogen enables the fine-tuning of the 
activity. New compounds 16a and 16b were 26 
and 22 times more active then ART, respectively 
[37b].
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The superior activity of deoxoartemisinin 3 
[21] encouraged the synthesis of a series of C(9)-
substituted derivatives 17 (Figure 6) [38, 39]. 
Derivatives 17a-h were 21–33 times more active 
then ART against the W2 clone and 50–70 times 
more active against the D6 clone, clearly demon-
strating that the removal of the lactone carbonyl 
provides excellent potency enhancement [38]. 
Those and some new derivatives [39] were tested 
in vivo both s.c. and p.o. The activity of derivative 
17a was superior to that of ART, curing all mice 
at 8 mg kg–1/day s.c. dose. 
Fig. 7. Structures and antimalarial activities of derivatives 18 and 19
A series of C(10) carbon heterocyclic sub-
stituted derivatives (Figure 7) of deoxyartemisi-
nin were synthesized using a short and efficient 
synthetic procedure [40]. The compounds were 
tested in vitro against CQS NF54 P.f. strain and 
demonstrated activity similar to that of ART. 
Derivative 18a was the most active in the series 
with an IC
50
 = 1.4 nM. The compounds 19a-d 
were also more stable at physiological condi-
tions then ART, and at the same time, retained 
very good to excellent activity [41]. Some of 
these derivatives are significantly more active 
(IC
50
 = 1.3–3.2 nM) than ART (IC
50
 = 9.9 nM) 
against the CQS NF54 P.f. strain.
Fig. 6. Structures and antimalarial activities of derivatives 3 and 17
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Hydrolytically stable C(10)-nonacetal ar-
temisinin dimers 20 (Figure 8), which possess 
phthalate derivatives as linkers, showed higher 
in vitro antimalarial activities against the CQS 
NF54 P. f. strain than ART, with 20a and 20b 
being the most active [42]. These two dimers 
were 3 times and 37 times more efficacious then 
artesunate 8c when administered s.c., and 20b 
was 1.5 times more efficacious then 8c (p.o.).
A new generation of ART dimers with 
excellent in vivo activity in P. berghei infected 
mice was developed [43, 44]. Eleven new de-
rivatives 21–27 (Figure 9) showed curative ac-
tivity at 3 × 30 mg kg–1 oral doses. At this dose 
the average mouse survival period was ≥3 times 
longer in comparison to artesunate 8c (>30 days 
for derivatives 21–27 vs. 7 days for 8c) [44].
Fig. 8. Structures and antimalarial activities of dimers 20
Fig. 9. Structures of derivatives 21–27
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4. ARTEMISONE (ARTEMIFONE®)
With the aim to prevent metabolic trans-
formation of artemisins to DHA and with 
the drive to improve PK characteristics, sev-
eral 10-(alkylamino)artemisinins 28 were de-
signed (Figure 10) [45, 46]. All of the tested 
compounds showed excellent in vivo activities 
against P. berghei, with 28c as the most ac-
tive derivative being almost 25 times (s.c.) and 
7 times (p.o.) more active than artesunate 8c. 
Unfortunately, 28c suffers from serious neuro-
toxicity even at low doses, thus pointing out 
once again that more lipophilic compounds 
are more toxic [46]. However, derivative 28e 
(artemisone, Artemifone®) showed no toxicity 
[47] and had tractable physicochemical prop-
erties. 
Fig. 10. Structures and antimalarial activities of derivatives 28
A detailed antimalarial efficacy and drug-
drug interaction study of artemisone 28e was 
performed [48]. It was shown that the in vitro 
antimalarial activities of artemisone against 12 
different P. falciparum strains were compara-
ble (exhibiting a mean IC
50
 value of 0.83 nM), 
independent of their drug-susceptibility profile 
to other antimalarial classes [46, 48]. During 
examination of the in vitro drug–drug interac-
tion against drug sensitive 3D7 and multidrug 
resistant K1 strains, it was noticed that artemi-
sone shows slight antagonistic effects with CQ, 
amodiaquine, tafenoquine, atovaquone or py-
rimethamine, and slight synergism with MFQ. 
In vivo screening using the 4-day Peters test 
against drug-susceptible (NY), primaquine-
resistant (P) and sulfadoxine/pyrimethamine-
resistant (KFY) lines of P. berghei, CQR (NS) 
and artemisinin-resistant lines of P. yoelii NS 
and drug-susceptible P. chabaudi (AS) showed 
artemisone has superior ED
50
 and ED
90
 activity 
in comparison with artesunate 8c. Artemisone 
exhibited 7 times greater activity (lower dos-
age) than artesunate (artemisone ED
90
 = 12.13 
mg kg–1 vs. artesunate ED
90
 = 87.50 mg kg–1) 
against the P. yoelii artemisinin-resistant line. 
The above results appear quite important in 
light of the recent isolation of artemether-re-
sistant P. falciparum strains from humans [10] 
and emerging evidence for resistance in vivo, 
suggesting more potent derivatives may be effi-
cacious where first generation compounds fail.
During in vivo drug–drug interaction 
examinations against the drug-susceptible P. 
berghei NY and the MFQ-resistant P. berghei 
N1100 lines, artemisone showed synergism 
with MFQ against both parasite lines. In com-
bination with CQ, no interaction against drug-
susceptible P. berghei NY parasites was de-
tected, however, a synergistic effect against the 
CQR line, P. yoelii NS, was observed.
No DHA had been produced after 30 min 
when isotopically labelled artemisone 28e* 
(Scheme 3) was incubated with human liver 
microsomes, but only dehydrogenated 31 and 
mono-hydroxylated metabolites 29, 30 and 
32, 33, with syn-hydroxy and peroxide groups 
(Scheme 3) [46], clearly distinguishing artemi-
sone and the compounds from the first genera-
tion artemisinins. Isolated artemisone metabo-
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lites were tested against the P. falciparum K1 
strain and were also found to be potent antima-
larials, with 30 and 31 being the most active 
(30: IC
50
 = 5.51 nM and 31: IC
50
 = 4.26 nM, 
artemisone: IC
50
 = 1.99 nM) [46, 49].
Scheme 3. Metabolic transformation of 28* and structures of obtained metabolites
In preclinical studies, artemisone showed 
enhanced efficacy and improved PK in compar-
ison to artesunate and did not demonstrate neu-
rotoxicity in vitro and in vivo [46, 49], which 
is a characteristic of the artemisinin derivatives 
that currently are used in clinical treatment 
[50]. Artemisinin was well tolerated during 
administration of artemisone as a single dose 
(10 mg to 80 mg) or multiple doses (40 mg or 
80 mg given once daily for 3 days). It appears 
that artemisone is devoid of time dependent PK 
(unlike artemisinin and artemether), with com-
parable C
max
, AUC, and t
½
 values after the first 
and third doses following the 3-day regime. Al-
though not being as active in vitro as the parent 
drug, the relatively high concentrations of me-
tabolites obtained after artemisone administra-
tion probably add to the overall parasiticidal ef-
fect of artemisone [49]. In vivo testing on non-
immune Aotus monkeys infected with P. falci-
parum showed that a single dose of artemisone 
(10 mg kg–1) in combination with single doses 
of MFQ (12.5 mg kg–1 or 5 mg kg–1) cleared 
parasitemia by day 1, with complete cure for all 
four monkeys tested [51]. With a single dose of 
mefloquine (2.5 mg kg–1) parasitemia was cleared 
by day 1, but without cure. For 3 days of treat-
ment with a combination of artemisone (10 mg 
kg–1day–1) and amodiaquine (20 mg kg–1day–1), 
all three monkeys tested were cured in contrast 
to those that were administered the individual 
drugs for 3 days. From this study, it is clear 
that various total dosages of artemisone (20 
to 90 mg kg–1) alone, administered over 1 to 3 
days, were unable to cure non-immune Aotus 
monkeys infected with P. falciparum. How-
ever, cure can be achieved when artemisone is 
combined with a single, sub-curative dose of 
MFQ, or with a 3-day treatment course of amo-
diaquine (or clindamycin).
5. 1,2,4-TRIOXANES
A very important finding was the high 
antimalarial activity of 1,2,4-trioxanes 34–39 
[52–55] (Figure 11), which are structurally 
much simpler than natural or semisynthetic 
ARTs. Observed antimalarial activity data 
significantly contribute to understanding the 
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minimum structure requirements for exhibiting 
good anti-plasmodial activity. Small stereo or 
structural differences have significant contri-
bution to the activity, e.g., epimers 34 showed 
different in vitro activity [52], or in the case of 
derivatives 35 where methyl substituents are re-
placed with spirocyclopentyl groups [52]. Con-
trary to observed stereoselectivity, the enanti-
omers of 36a and 36c or 36b and 36d showed 
very close activities, suggesting that cis-fusion 
significantly contributes to the activity [53]. In-
troducing fluorine atoms greatly enhanced activ-
ity. As measured in the 4-day Peters suppressive 
test, derivative 36b (Fenozane B07) showed an 
ED
50
 of 2.5 mg kg–1day–1, an order of magnitude 
more effective than 36a with an ED
50
 of 25 mg 
kg–1day–1. Other derivatives of this group, like 
ethers, alcohols or acids are far less active when 
compared with Fenozane. Probably, epimers 
37 are the most interesting examples where the 
change of the configuration at one stereocentre 
dramatically changed the activity [54]. A similar 
structure-activity relationship, SAR, could be de-
veloped for 38 and 39 [55].
Fig. 11. Structures and antimalarial activities of derivatives 34–39
Trans-fused derivatives 40–43 (Figure 
12) also exhibited high activities [56]. They 
caused 96–100 % suppression of parasitemia 
on day 4 after 96 mg kg–1day–1 p.o. dose, with 
spirocycloheptane 42 as the most active. Al-
though trioxanes 40–43 are somewhat less ef-
fective than β–arteether under the same test 
conditions (100 % of suppression at 48 mg 
kg–1day–1), the obtained results suggest that 
trans-fusion may also provide good antima-
larial activity, and that some other structural 
aspects additionally should be taken into con-
sideration. Accordingly, cis-fused trioxane 44 
(Figure 12) showed IC
50
 and IC
90 
values of 
893 nM and 1845 nM, respectively, against a 
W2 P. falciparum clone, while under the same 
screening conditions, cis-fused trioxane 36a 
also showed 15 nM and 36 nM efficacies, re-
spectively [57].
For trioxanes 45–51 (Figure 12), struc-
tures were further simplified and still retained 
high activity. Different starting compounds, 
such as geranyl acetate [58] (trioxanes 45), 
cyclopropyl or phenyl allylic alcohols [59] 
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(trioxanes 46), aryl substituted allyl alcohols 
(trioxanes 47) [60] or methyl substituted allyl 
alcohols (trioxanes 48 and 49) [61] were used 
for obtaining β-hydroxyhydroperoxides.These 
β-hydroxyhydroperoxides were later coupled 
to different carbonyl compounds, and very ac-
tive trioxanes with diversified structures were 
obtained [62, 63]. 2-Adamantyl derivatives 
45–48 were the most active against multidrug 
resistant P. yoelli in mice and exhibited 100% 
suppression of parasitemia on day 4 at 96 and 
48 mg kg–1 × 4 days (Peters test) doses p.o. The 
most active 2-fluorenyl derivate 47c showed 
100% suppression of parasitemia on day 4, 
even at 24 mg kg–1 × 4 days, which appeared 
to be a half effective dose of arteether [60]. 
Intramuscular injection decreases the activi-
ties of these derivatives and thus confirmed, 
once again, that hydrophobic compounds 
show better bioavailability by oral route. De-
rivatives 48 and 49 with C(5)-alkyl substi-
tuted 1,2,4-trioxane rings were tested against 
the CQR K1 P.f. strain and showed activities 
which strongly depend on C(3)-substituents. 
While spiroadamantane derivates 48 were as 
active as ART, gem-dimethyl derivative 49 
was 270 times less active [61]. Replacing 
spiroadamantyl with a spirocyclohexyl group 
bearing an ionizable arylamino moiety, as in 
50 [62] or other polar groups as in 51 [63], 
also resulted in loss of the activity. Although 
some derivatives such as 51a and 51b [63] 
exhibit 100 % suppression of parasitemia on 
day 4 at 96, 48, and 24 mg kg–1 × 4 day doses 
p.o., in general, these compounds are less po-
tent than adamantyl derivatives. These results 
convincingly introduce the adamantyl-spiro-
1,2,4-trioxane motif as significant contributor 
to good antimalarial activity.
The antimalarial activities of a series of 
steroids possessing the 1,2,4-trioxane moiety 
(52–54 (Figure 13), respectively) were also 
tested [64]. Only pregnane-based trioxanes 
53a-f exhibited good activity. They showed 
100% suppression of parasitemia on day 4 and 
40–100 % protection at 96 mg kg–1 × 4 day 
doses, with 53b being the most efficacious. 
Cholestane- and tigonenin-based derivatives 
were much less successful with 15–73% sup-
pression.
Fig. 12. Structures and antimalarial activities of derivatives 40–51
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Scheme 4. Griesbaum co-ozonolysis
Fig. 13. Structures of steroid based 1,2,4-trioxanes 52–54
6. 1,2,4-TRIOXOLANES (ARTEROLAN)
1,2,4-Trioxolanes, ozonides, a very well 
known class of organic compounds, appear as 
intermediates during scission of olefins into 
carbonyls during ozonolysis. It was an un-
expected and surprising discovery [65] that 
ozonides are relatively stable and that many 
express excellent activity against malaria par-
asites, like the structurally similar 1,2,4-triox-
anes.
6.1. First generation 1,2,4-trioxolanes 
(OZ209, OZ277 and OZ339)
1,2,4-trioxolane 57 was obtained by 
Griesbaum co-ozonolysis of suitable methyl 
oximes 55 and ketones 56 (Scheme 4) [66, 
67]. Synthesis of a vast array (Figures 14 and 
15) of differently substituted derivatives is en-
abled with the applied method and the stability 
of the 1,2,4-trioxolane moiety to reduction and 
alkylation conditions [68].
Usually, 1,2,4-trioxolane antimalarials 
are prepared in 1 to 4 steps, depending on the 
modifications required [66, 67, 69, 70, 71] af-
fording the final products in yields up to 75 %. 
The vast majority of these antimalarials are 
achiral, which greatly facilitates production in 
the developmental step. The advantage of ozo-
nide (OZ) antimalarials is the use of the ada-
mantane moiety that has lipophilic functional-
ity, allowing the opposite part of the molecule 
to be fine-tuned using a number of polar func-
tional groups, preferably basic in nature [65, 
66, 68, 70, 71]. Many of the so obtained OZ 
compounds are active in all stages of devel-
opment of the malaria parasite, and are more 
active than artemether and artesunate, both in 
vivo and in vitro. 
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Fig. 14. Structures of trioxolanes 58–67.
When compared with other OZ compounds, 
trioxolanes OZ209 (59 as mesylate, Figure 14) 
and OZ277 (60 as tosylate, Arterolan, Figure 14) 
showed superior PK results, such as prolonged 
half-life and enhanced bioavailability after a single 
oral dose. Compound OZ209 had somewhat better 
antimalarial results and a lower recrudescence level. 
However, OZ277 was chosen as the development 
candidate, primarily because of its improved toxico-
logical profile and reduced concentrations in brain 
tissue after oral dosing [65]. For example, 2 hours 
after dosing, both OZ209 and OZ277 were distrib-
uted throughout the liver, kidney, lung and heart, 
while after 18 hours, OZ277 was detected only in 
the lungs and in several-fold lower concentrations 
than OZ209. 
Unlike OZ209, which was quantified in 
brain tissue after both 2 h and 18 h, OZ277 
could not be quantified in this organ. In view 
of potential neurotoxicity issues, these find-
ings were taken as a considerable advantage 
of OZ277 over OZ209. Trioxolane OZ277 ap-
peared quite stable to metabolic transformation 
(t
½
 = 1.4 h, p.o. in healthy rats) [65]. The oth-
er derivatives 58, 61–67 (Figure 14) afforded 
further insight into SAR in the context of the 
physico-chemical, biopharmaceutical, and toxi-
cological profiles of trioxolanes [70].
Recently [72], the same authors revealed 
data for a series of OZ compounds with weak 
base functional groups, which were responsible 
for high antimalarial efficacy in P. berghei-
infected mice. Their antimalarial efficacy and 
ADME profiles are equal or superior to OZ277. 
One of the most promising is OZ339 (Table 3, 
as the tosylate salt). Despite the obvious differ-
ence in in vitro activity, both ozonides eradicate 
parasitemia below the detectable level one day 
after administration (99.9 %, 1×10 mg kg–1, and 
3×3 mg kg–1). The drug candidate OZ277 is a 
powerful fast-acting antimalarial with a 67 % 
cure record at a 3×10 mg kg–1 dosage (mice) 
[65]. However, at a 3×3 mg kg–1 dosage, the 
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T a b l e 3
Comparative data for fast-acting antimalarials: 60 (OZ277), 67 (OZ339) 
and sodium-artesunate 8c
IC
50
 (ng/ml) Activity (%)
p.o.
In vivo activity
(3×3 mg kg–1, p.o.)e
Comp. K1 NF54 (1×10 mg kg–1)c ERd
Activity 
(%)
Survival 
(days)
Curef 
(%)
t
½
(i.v., min)
67 (OZ339)a,b 0.35 0.39 >99.9 0.45 >99.9 27.0 60 83
60 (OZ277)a,b 1.0 0.91 99.9 0.32 >99.9 11.4 0 76
8c (AS)b 1.3 1.6 67 0.43 70 9.2 0 40g
a  Tosylate salt. 
b  Taken from ref. 70. 
c  Groups of five P. berghei-infected NMRI mice were treated orally on day +1 (1×10 mg kg–1). Activity measured on day +2. 
d  Predicted hepatic extraction ratios (ER) using human microsomes. 
e  Groups of five P. berghei-infected NMRI mice were treated orally on days +1, +2, and + 3 (3×3 mg kg–1). 
  Activity measured on day +4.
f  Percent of mice alive on day 30 with no evidence of blood parasite. 
g  Taken from ref. 66. N.D. not dosed.
As mentioned above, the tolerance of 
the 1,2,4-trioxolane moiety to diverse reaction 
conditions [67] enabled the synthesis of a sig-
nificant number of derivatives. Many of them 
showed very good antimalarial activity, like 
derivatives 68–72 (Figure 15) [73], piperidine 
derivatives 73–75 [74] and derivatives which 
contain aliphatic and aromatic amino function-
al groups or azole heterocycles as substituents 
(76–82) (Figure 15) [71]. Lack of activity of 
83 indicates the essential contribution of the 
spiro-adamantane system to the antimalarial 
properties of this class of compounds.
Many of the examined derivatives exhib-
ited excellent in vitro results, but failed during 
in vivo tests, toxicity trials or metabolic sta-
bility and bioavailability tests. More lipophilic 
trioxolanes tend to have better oral activities 
and are metabolically less stable than their 
polar counterparts. Such behaviour is consist-
ent with results obtained for other classes of 
synthetic peroxides. Trioxolanes with a wide 
range of neutral and basic groups had good 
antimalarial profiles unlike derivatives with 
acidic groups. Based on the collected exten-
sive screening results the authors concluded 
that the in vitro activities of 1,2,4-trioxolanes 
are not (always) a reliable predictor of in vivo 
potency [73]. Rather, their experiments in P. 
berghei-infected mice confirmed that in vivo 
same compound cured no mice, while trioxo-
lane OZ339 cured 3/5 mice with an excellent 
survival time of 27 days (OZ277 had 2.4 times 
lower survival time). These good PK charac-
teristics were underlined by the favourable p.o. 
bioavailability data for OZ339, 78% vs 26% for 
OZ277. In all experiments, artesunate showed 
inferior activity. Inhibition assays revealed that 
OZ339, like OZ277, did not inhibit CYP3A4, 
CYP2C9, and CYP2D6 at concentrations up to 
50 μM. Finally, preliminary toxicological ex-
periments indicated that OZ339 was minimally 
toxic (liver) and, similarly to OZ277, demon-
strated no detectable signs of neurotoxicity.
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results were essential for compound differen-
tiation and selection for further metabolic and 
pharmacokinetic profiling [72]. 
Following the recommendation of WHO 
for R&D of artemisinin-based combination 
therapies (ACT), OZ277 entered Phase III 
clinical trials in combination with piperaquine 
(arterolane maleate + piperaquine phosphate) 
[72]. In 2011, Ranbaxy received permission 
from the Indian Drug Regulator, Drug Con-
troller General of India (DCGI), to manufac-
ture and market this drug in India as Synriam®, 
for the treatment of uncomplicated malaria in 
adults [75]. 
6.2. Second generation 
of 1,2,4-trioxolane: OZ439
Although entire anti-malarial pro-
files show superior properties of OZ277 and 
OZ339 in comparison to DHA, the search for 
an ozonide with significantly increased half-
life continued. 
Fig. 15. Structures and antimalarial activities of derivatives 68–83
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As a result, very recently the screening 
results of second generation of ozonide anti-
malarials were revealed [76]. Of the several 
very active derivatives of undisclosed struc-
ture, it appears that the most promising anti-
malarial candidate is OZ439 [76] (Table 4). 
The initial results indicate that this compound 
provides a single-dose oral cure in a murine 
malaria model at 20 mg kg–1, a situation not 
known for any of peroxide antimalarials, ex-
cept for artelinic acid at more than 7 times 
higher dose. The second-generation ozonide 
OZ439 completed Phase I studies and is cur-
rently undergoing Phase II clinical trials. The 
prolonged blood stability, significantly high 
bioavailability (76 % for OZ439 vs 13% for 
OZ277) and improved PK characteristics (Ta-
ble 4) led to positioning of OZ439 as current 
major OZ drug candidate – postinfection cure 
(3×5 mg kg–1day–1 and 20 mg kg–1 single dose), 
and exclusive prophylactic characteristics (Ta-
ble 4). The absence of metabolic products sig-
nificantly contributes overall to OZ439 rela-
tive to other peroxide antimalarial drugs [76]. 
T a b l e  4
Comparative data for first and second generation of ozonide antimalarials:  
60 (OZ277) vs. 84 (OZ439)
IC
50
 (ng/ml) Postinfection (%) p.o.c In vivo prophylactic activity p.o.
(1×30 mg kg–1)e
Compound K1 NF54 1×30 mg kg–1 Cured
Activity 
(%)
Survival 
(days)
Cured 
(%)
t
½
 (p.o., min)
60 (OZ277)a,b 0.71 0.63 99.9 0 0 7 0 55
84 (OZ439)b 1.6 1.9 >99.9 100 99.8 >30 100 1380
8c (AS)b 1.2 1.5 92 0 21 7 0 40f
a  Tosylate salt. 
b  Taken from ref. 76. 
c  Groups of P. berghei-infected ANKA mice (n =5) were treated orally on day +1 (1×30 mg kg–1). Activity measured on day +3. 
d  Percent of mice alive on day 30 with no evidence of blood parasite. 
e  Groups of P. berghei-infected ANKA mice (n =5) were treated orally on day -1 (1×30 mg kg–1). Activity measured on day +3. 
f  Intravenous, taken from ref. 66. 
7. 1,2,4,5-TETRAOXANES
3,6-Substituted derivatives of 1,2,4,5-tetraox-
acyclohexane (1,2,4,5-tetraoxane) have been known 
for many years and were used for different purposes 
[77]. They are readily formed by acid-catalyzed [78] 
peroxyacetalization of carbonyl compounds with 
hydrogen peroxide or bis-trimethylsilylperoxide 
[79–81] or other procedures [82]. The discover-
ing that inexpensive tetraoxane 3,6-dicyclohex-
ylidenes exhibit pronounced antimalarial activ-
ity opened new possibilities in combating this 
disease. A real breakthrough was achieved with 
steroidal tetraoxanes – with these derivatives 
the high potency of tetraoxanes for treatment of 
P. falciparum CQR strains was shown [80, 98] 
For that reason, many efforts have been made in 
finding better procedures for synthesizing and 
designing new derivatives with improved ac-
tivities [83]. Many of them have been reviewed 
and their antimalarial activities analyzed [7f, 
7g, 84].
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After the first report where they were 
described [85], mixed tetraoxanes3 drew sig-
nificant attention. Since then, some new proce-
dures for their synthesis [86, 87], or the synthe-
sis of gem-dihydroperoxides as key precursors 
[88] were developed with the aim to improve 
the yields of tetraoxane compounds. 
A new group of mixed dicyclohexylidene 
tetraoxanes, bearing polar, neutral, or basic 
groups, demonstrated high activities against 
both CQS and CQR P.f. strains (Figure 16) [89]. 
The goal was to obtain the simplest amphiphi-
lic structures of the kind and to minimize the 
influence of steric effects on antimalarial activ-
ity. Besides that, stability under basic, acidic, 
oxidative, reductive and reductive amination 
conditions revealed significant stability of the 
tetraoxane moiety that enabled the synthesis 
of a variety of derivatives [89c]. Interestingly, 
the most active compounds within the group 
of dicyclohexylidene tetraoxanes 85–94 have 
very close activities disregarding the presence 
of neutral (87, 92), polar protic (86) or basic 
ionizable groups (85, 88–91, 94). Such conduct 
impedes profound SAR analysis. In the present 
set of derivatives, amines 88 and 89 were the 
most active in vivo. They both cured 5/5 mice 
at 300 mg×kg–1day–1 doses s.c. in a modified 
3	 Term	“mixed	tetraoxanes“	describes	1,2,4,5-tetraoxacyclohexanes	
possesing	nonidentical	substituents	at	positions	3	and	6.	
Thompson test. With 150 mg×kg–1day–1 doses 
s.c. 88 retains the same efficiency, but 89 was 
less active with 4/5 cured mice.
A structurally similar group was syn-
thesized [90] using the procedure previously 
applied to this class of compounds (Figure 
17) [85, 89a]. The compounds were screened 
against CQS P.f. strain 3D7 and the most active 
derivatives 95–101 have the activities within 
the same range as ones described above. The 
least active derivatives 100 and 101 confirmed 
the superiority of the 3,6-dispiro-1,2,4,5-tetra-
oxane structural motif. Adamantyl derivatives 
98 and 99 [90] showed 100 % inhibition by p.o. 
administration at 30 mg kg–1 doses, and deriva-
tive 99 had superior ED values against P. berg-
hei (ANKA) as compared to artemether: ED
50
 
= 3.18 mg kg–1 and ED
90
 = 3.88 mg kg–1 for 99; 
ED
50
 = 5.88 mg kg–1 and ED
90
 = 10.57 mg kg–1 
for artemether. 
The ability of adamantyl substituent to 
stabilize the structure and to improve the anti-
malarial activity was additionally exemplified 
with a new series of amphiphilic adamantyl-
based mixed tetraoxanes (Figure 18) [91]. The 
derivatives that contain polar sulphonamide ex-
hibit activities in 3–30 nM range, with 102–105 
as the most active compounds against 3D7 P. 
f. strain. In addition, derivative 102 was tested 
versus seven additional strains of P. falciparum 
and exhibited activity in the 1.9 – 3.8 nM range. 
Fig. 16. Structures and antimalarial activities of derivatives 85–94.
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Fig. 17. Structures and antimalarial activities of derivatives 95–101
Compounds 102 and 104 were noticeably ac-
tive in vivo (p.o., P. berghei ANKA): ED
50
 = 
6.61 mg kg–1 for 102 and ED
50
 = 7.93 mg kg–1 
for 104, with ED
50
 = 8.42 mg kg–1 for ART for 
comparison).
Further structure optimization brings up 
derivative 106 (RKA182) as a lead compound, 
with selected formulation as its ditosylate salt 
[92]. Synthesis of 106 were developed on high 
scale employing Re
2
O
7
 as a mild Lewis acid cat-
alyst during peroxyacetalysation with hydrogen 
peroxide [93]. The compound exhibits superior 
in vitro activity, which is additionally confirmed 
by in vivo and ADME results. It shows 100% 
suppression activity after 30 mg kg–1 dose on 
day 4 in Peters test, and in vivo activity with 
an ED
50
/ED
90
 of 1.33/4.18 mg kg–1 (P. berghei 
ANKA), which is superior to artemether and 
artesunate, and comparable to artemisone. In 
an assessment of efficacy in P. berghei-infected 
mice, the administration of 3 consecutive 10 mg 
kg–1 oral doses of 106 and artesunate results in 
the survival of 22 mice in comparison to 9 for 
artesunate. Even though no specific metabo-
lites of 106 were identified, Phase I metabolic 
pathways for the compound class were identi-
fied as adamantane/cyclohexane hydroxylation, 
N-oxide formation and N-dealkylation. With the 
Fig. 18. Structures and antimalarial activities of derivatives 102–106
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exception of weakly inhibiting CYP2C19 (IC
50
 
at 59 mM), 106 did not inhibit any of the ma-
jor human CYP450 isoforms at concentrations 
up to 100 mM. In PK experiments in rats con-
ducted over 6 h, 106 (1 mg kg–1 intravenous and 
10 mg kg–1 oral doses) had an oral C
max
 of 90 
ng/ml, intravenous and oral half-lives of 0.80 
and 2.4 h, CL of 136 ml/min/kg, Vd of 9.5 l/kg, 
and an oral bioavailability of 40%. In toxicity 
experiments, the maximum tolerated dose of 14 
in rats was 400 mg kg–1.
Some other types of tetraoxanes were 
less successful. Such examples are symmetri-
cally substituted 3,3,6,6-tetraalkyl-1,2,4,5-
tetraoxanes derived from acyclic ketones [94] 
and symmetric and nonsymmetric 1,2,4,5-tetra-
oxane derivatives of substituted benzaldehydes 
(Figure 19) [95]. Compounds were tested as 
mixtures of corresponding isomers and in gen-
eral exhibited rather poor antimalarial activ-
ity against both CQS and CQR P. falciparum 
strains. Within the series of acyclic derivatives, 
compounds 107–109 were the most active, but 
still they were 1.6 – 2.2 times less active than 
corresponding tetraoxanes 110 derived from 
cyclohexane, or 40–50 times less active than 
artemether [94]. Within the benzaldehyde se-
ries compound 111 was the most active, while 
the other members were significantly less ac-
tive with IC
50
’s in the range 1.4–17 μM [95], 
which is far less then corresponding 1,2,4,5-te-
traoxanes or 1,2,4-trioxanes considered as ac-
tive. Nonetheless, these results offer valuable 
basic information for the correlation between 
the structure and antimalarial activity of the 
simple peroxides.
1,2,4,5,7,8-Hexaoxonanes are customary 
side products of the synthesis of 1,2,4,5-tetra-
oxacyclohexanes (Figure 20). Their activities 
against K1 and NF54 P. f. strains showed that 
hexaoxonanes 112–118 are convincingly less 
active than the corresponding tetraoxanes, with 
3-4 orders of magnitude lower IC
50
’s [96]. Since 
peroxide bonds are essential for antimalarial 
activity, such poor efficiency was attributed to 
steric hindrance. Analogous behaviour was no-
ticed with asymmetric 1,2,4,5,7,8-hexaoxonane 
118 as well [89c].
The first described steroidal 1,2,4,5-tetra-
oxane antimalarials 120 and 121 were derivative 
from 5a-cholestane-3-one (Figure 21) [81]. Al-
though tetraoxane 107 was less active in com-
parison to ART (IC
50
 (D6) = 155 nM), the result 
of this pioneering research clearly showed that 
even complex molecules such as steroids could 
be good carriers of the tetraoxane pharmaco-
phore. Replacing cholestane with derivatives of 
cholic acid significantly improved antimalarial 
activity (Figure 21) [80, 97]. Compounds ob-
tained as a series of diastereomers were named 
as cis-C(2)C(2a) and trans-C(2)C(2a) and they 
showed moderate to high activity against both 
CQS and CQR strains. The most active were 
primary amide 122 (IC
50
(W2) = 18.79 nM) and 
Fig. 19. Structures and antimalarial activities of derivatives 107–111
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N-propyl amides 123 and 124 (IC
50
(D6) = 9.29 
nM and 20.08 nM, respectively). 
Replacing one steroid with a simpler al-
kylidene moiety enabled the synthesis of the sec-
ond generation of steroidal tetraoxanes based on 
cholic acid derivatives. Starting from 4-alkyl [98, 
99], 4-aryl [100], 4-carboxy substituted cyclo-
hexanones [101] and the acetone [102] afforded 
the synthesis of a number of various derivatives 
(Figure 22). The stability of the tetraoxane moi-
ety under a range of reaction conditions enabled 
the synthesis of diverse derivatives [89c]. Some 
of the shown mixed steroidal tetraoxanes exhib-
ited impressive in vitro and in vivo antimalarial 
activity. Contribution of cholic acid moiety as a 
carrier is clearly emphasized by the pronounced 
activity of derivative 132, since bis-isopropyli-
dene tetraoxane was completely inactive [103]. 
When administered to mice (p.o., P. 
berghei KBG 173 strain) tetraoxane 126 in the 
Thompson test cured 4/5 mice at 200 mg kg–
1day–1 doses, while being moderately active when 
applied at 50 mg kg–1day–1 (cured 2/5) [98]. The 
administration of tetraoxane 131 (p.o.) cured 2/5 
mice at 320 mg kg–1day–1 doses, however, the 
same compound was more efficient at 160 mg 
kg–1day–1 s.c. doses, with 5/5 cured mice [102]. 
All cured mice had negative blood smears with-
in all days tested (6–31). Tetraoxane 134 cured 
5/5 mice at 320 mg kg–1day–1, and using lower 
doses (80 mg kg–1day–1) demonstrated moderate 
activity with 3/5 cured mice [99]. It should be 
Fig. 20. Structures and antimalarial activities of derivatives 112–119
Fig. 21. Structures of derivatives 120–124
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emphasized that all these compounds showed 
no toxic effect against tested animals at any 
applied concentrations. In addition, they have 
low activity against the Vero cell line, show-
ing a cytotoxicity/antimalarial potency ratio 1/
(1400–9500) [98]. Furthermore, the n-propyl 
amide 127, revealed no healthy erythrocyte 
(RBC) membrane lysis [104], suggesting that 
the antimalarial activity of these compounds 
is the consequence of an interaction specific to 
infected RBCs, and is not the result of uncon-
trolled RBC membrane lysis.
A series of tetraoxanes based on deoxy-
cholic derivatives were prepared with the aim 
to compare them to cholic acid-derived te-
traoxanes (Figure 22) [99]. In general, these 
compounds follow the same trends as the 
cholic acid derivatives: higher activity of 4ʹʹ-
methylcyclohexyl derivatives than nonsubsti-
tuted cyclohexyl ones and higher activity of 
4ʹʹR- over 4ʹʹS-epimers. However, tetraoxanes 
with deoxycholic acid-derived carriers are less 
active then corresponding cholic acid deriva-
tives suggesting that the C(7) acetyloxy group 
appreciably contributes to their antimalarial 
activity. Within this group of tetraoxanes, the 
derivatives 135 and 136 were the most ac-
tive exhibiting activities comparable to ART 
Fig. 22. Structures and antimalarial activities of derivatives 125–137
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and mefloquine. In vivo, compound 136 cured 
3/5 mice at 160 mg kg–1day–1 doses (p.o., P. 
berghei KBG 173 strain), however, at lower 
doses of 40 mg kg–1day–1, the activity sharply 
declined with no cured mice.
The only intramolecular steroidal 
1,2,4,5-tetraoxane 137 (Figure 22) tested up to 
now exhibited moderate in vitro antimalarial 
activity against P. falciparum strains (IC
50
(D6) 
= 0.63 μM; IC
50
(W2) = 0.52 μM) [105]. Re-
cently, Terent’ev et al. published the synthe-
sis of diverse intramolecular tetraoxanes from 
β-diketones and hydrogen-peroxide in the 
presence of strong mineral acids [106].
8. CHIMERIC PEROXIDE  –  QUINOLINE 
COMPOUNDS
A new concept for treating malaria was in-
troduced with chimeric peroxides, the compounds 
that possess covalently bonded two well-known 
pharmacophores – the quinoline functionality and 
peroxide moiety. The compounds were designed 
with the aim to overcome resistance of the para-
site to CQ-based drugs and to take advantage of 
the PK properties of trioxanes, ozonides and te-
traoxanes. The initial set of derivatives was more 
active against CQR strains, with compound 138 
as the most active against laboratory strains [107] 
and human isolates (Figure 23) [108]. 
Fig. 23. Structures and antimalarial activities of chimeras 138–146
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Certain simplifications of structure lead 
to trioxaquine 140 that was very active against 
both CQS and CQR strains of P. falciparum 
[109]: ED
50
 = 5 and 18 mg kg–1 day–1 (P. vinck-
ei), i.p. and p.o. administration, respectively. 
Parasitemia clearance, without recrudescence, 
was achieved after 18 mg kg–1 day–1 i.p. dose, 
and no toxic effects in mice were observed even 
at 120 mg kg–1 day–1 p.o. dose over four consec-
utive days. Coupling of the same trioxane ke-
tone and primaquine produced trioxaquine 141, 
which demonstrated significantly lower activ-
ity against all three examined strains, and thus 
limited this concept only to 4-aminoquinolines. 
Trioxaquine 142 also exhibited high in vitro and 
in vivo activity [110]. The compound completely 
cured mice infected with CQR strain P. vinckei 
and CQS strain P. vinckei in 30 mg kg–1day–1 p.o. 
doses.
Other variations of trioxane structures 
produced derivatives 143 [111] and 144 [112], 
which expressed lower activities.
Although some very active trioxaquines 
were prepared, the concept of these drugs did 
not justify itself for several reasons. First, these 
compounds did not show expected synergism, 
since in many cases parent trioxane ketones 
[103, 112] were more active than hybrids – see 
ketone 139 vs chimera 138 for comparison. In 
addition, 4-aminoquinolines 145 itself are anti-
malarials. They suppressed parasitemia in mice 
(i.m., 87–97%), but as with trioxaquines 144, 
no treated mice survived [112]. Even though 
some authors wish to establish these chimeras 
as therapeutics with dual activity [110, 113] all 
available evidence on the mechanism of anti-
malarial activity of trioxanes and 4-aminoquin-
olines points out that they have the same target 
[110]. Lastly, many of these hybrid molecules 
were tested as inseparable mixtures of diaste-
reomers. These circumstances deprive one of 
the possibilities to realize the actual scope of 
the antimalarial capacity of these compounds.
Based on the same concept and enhanced 
activities of trioxolanes with the basic side 
chain, chimeric trioxolane 146 was obtained 
(Figure 23) [114]. Although it is very active, in 
vitro against K1 and NF54 strains and in vivo 
against ANKA strain of P. berghei, 146 did not 
achieve the synergic effect of two pharmacoph-
ores, especially when compared to trioxolanes 
76 and 80.
Another variations of trioxane hybrid an-
timalarials were made with covalently bonded 
DHA and C(18)-quinine acid 147 (Figure 24) 
[115]. Two segments were bonded with a hy-
drolytically labile ester bond, and it is possible 
that under physiological conditions, hybrid 148 
Fig. 24. Structure and antimalarial activity of derivatives 147 and 148
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actually delivers two active agents. This ap-
proach seems to be logical since there is evi-
dence that ARTs and quinine are active during 
the same stage of the P. falciparum life cycle 
[116], but differ in mechanism of action [115]. 
Obtained results showed that hybrid 148 had 
significantly higher antimalarial activity than 
ART and quinine alone, or when it is compared 
to an equimolar mixture of ART and quinine. 
However, the observed results would be more 
significant if the authors compared hybrid 148 
to DHA rather than ART or/and to acid 147. 
Based on data obtained from research on 
the mechanism of tetraoxane action [101] (vide 
infra) chimeric tetraoxaquines were designed 
with the aim to exert effects of the presence of 
two pharmacophores within the same molecule 
(Figure 25) [117]. Three of them were as active 
as ART or MFQ against tested strains of P. fal-
ciparum, and all of them showed higher activity 
than CQ against CQR strains. Although a syn-
ergic effect was not achieved, it should be not-
ed that the derivatives exhibited higher activity 
than non-chimeric derivatives having related 
structure (compare 149 to 85, 150 to 90 and 91, 
151 and 152 to 133) [89c]. In vivo experiments 
(p.o., P. berghei KBG 173 strain) revealed that 
derivatives 149 and 150 cured all tested mice at 
320 mg kg–1day–1 doses. At lower doses of 80 
mg kg–1day–1 the derivatives were less effective, 
however, they still cured 3/5 of examined mice. 
Both compounds have minimum active doses 
(MAD) of 20 mg kg–1day–1 with no toxic effects 
even at the highest applied dose of 960 mg kg–1.
Fig. 25. Structures and antimalarial activities of derivatives 149–152
9. METABOLISM AND DRUG  
COMBINATION ASSAYS
Although significant numbers of 
1,2,4,5-tetraoxane antimalarials have been re-
ported and some exhibit extraordinary antima-
larial activity, their pharmacological properties 
have been much less explored than those of 
1,2,4-trioxanes. Vennerstrom and co-workers 
were the first to give detailed metabolic and 
pharmacological profiles of tetraoxanes [118]. 
It was shown that the compound 153 (Figure 
26) is synergistic with MFQ and quinine against 
both CQS D6 and CQR W2 P. f. strains. Tetra-
oxane 153 is also synergistic with CQ, unlike 
ART that shows an additive effect with CQ and 
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synergism only at high concentrations [119]. In 
addition, 153 is synergistic with ART in con-
trast to other semisynthetic derivatives which 
have uniformly additive effects. Derivative 153 
is a modest inhibitor of human CYP1A2 activ-
ity and has a different metabolic pathway ver-
sus ART. Artemisinin induces its own metabo-
lism [118, 120] and is metabolized by CYP2B6, 
CYP2C19 and to a less extent by CYP3A4. 
Tetraoxane 153 is most likely metabolized by 
CYP1A2 and unlike artemisinin, 153 has pro-
phylactic activity protecting 4/7 mice against P. 
berghei. These results suggest that tetraoxanes 
have different metabolic pathways with regard 
to ART and may have a somewhat different 
mechanism of action. Šolaja et al. reported the 
results of metabolic stability assays and meta-
bolic identification for many cyclohexylidene 
and steroidal mixed tetraoxanes [89b, 89c, 99, 
101, 102, 117]. Incubation of human, mouse, 
rat and rhesus monkey liver microsomes with 
examined compounds showed dissimilar half-
lives and various mono- and di-hydroxylated 
products, and the products of dehydration and 
deacetylation were detected as well. Unfortu-
nately, correlation of metabolic stability assays 
and proposed metabolite structures with the in 
vitro and in vivo antimalarial activities of these 
derivatives could not be carried out. It is impor-
tant to note that no products of peroxide bond 
cleavage were detected. Drug combination as-
says of tetraoxane 154 (Figure 26) showed 
that this derivative is additive with ART, DHA 
and artesunate 8c against both CQS (D6) and 
CQR (W2 and TM91C235) P. falciparum 
strains, however, tetraoxane 154 showed syn-
ergism with artelinic acid 10a against all three 
strains [121]. Tetraoxane 154 is additive with 
MFQ under high concentrations against D6 and 
TM91C235, but at low concentrations it ex-
hibits an antagonistic effect. With chloroquine, 
tetraoxane 154 showed antagonism against all 
three tested strains.
After incubation of ozonide 60 OZ277 
(Figure 14) with human liver microsomes in vi-
tro, three mono-hydroxylated metabolites were 
detected [122]. Two major metabolites 155 and 
156 (Figure 26) appeared after hydroxylation of 
the adamantane substructure. Both metabolites 
had low antimalarial activity with IC
50
 values 
> 245 nM against the CQR K1 P. falciparum 
strain.
Earlier in this text was mentioned that 
the incubation of isotopically labelled artemi-
sone 28e* afforded metabolites 29–33, with 
synhydroxyl and peroxide groups (Scheme 3) 
[46]. Incubation with microsomes and 14 re-
combinant CYP isoforms together with selec-
tive inhibitors showed that only recombinant 
CYP3A4 significantly metabolized 28, indicat-
Fig. 26. Structures and antimalarial activities of derivatives 153–156
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ing that artemisone and ART, in spite of being 
structurally similar, have different metabolic 
profiles in P. falciparum. Therefore, it is possi-
ble that they can exert their antimalarial activity 
through similar but not identical mechanisms.
It is especially interesting, and should be 
underlined, that a common denominator in met-
abolic transformation is the iron species in the 
haem prosthetic group of CYPs, which could 
take part in Fenton chemistry with organic per-
oxide. However, during the described interac-
tion of all these structurally diverse compounds 
with CYP enzymes, peroxide bond scission 
never occurred. 
10. MECHANISM OF ACTION
Many research groups were involved in 
solving the mechanism of action of antimalarial 
peroxides, and plenty of reports can be found 
on this subject. However, the scientific litera-
ture is largely controversial, and many authors 
disagree about the site of action, putative target 
and lethal reaction species, and the actual kill-
ers of the parasite. 
Several groups investigated the mecha-
nism of action for more than fifteen years [123–
127]. In general, it was found that the process 
starts with the formation of oxygen radicals 157 
and 158, which arise upon homolytic peroxide 
bond scission in the presence of ferrous ions 
(Scheme 5). It is assumed that ions 157 and 
158 undergo intramolecular rearrangements 
(1,5-hydrogen shift and β–scission) to form C-
radicals 159 and 160. Both O- and C-centred 
radicals are highly reactive species and are le-
thal to parasites. During these processes, one 
or more intermediates probably reacts with vital 
biomolecules, inhibits their activity and causes 
the parasites to die. It was proved that one of 
the side products is high-valent iron-oxo species 
Fe(IV)=O, which could also be toxic to the para-
site [128, 129]. In the absence of a suitable target 
that would be alkylated the products 161 and 162 
were formed [127b]. The adducts 163–167 (Fig-
ure 27) were found to be indicative of primary and 
secondary radicals and the ability of ART and its 
derivatives to act as alkylating agents [123c, 126, 
127]. The results obtained with artesunic acid and 
trioxaquine 140 additionally confirmed the capa-
bility of peroxides or chimeras to alkylate haem 
[130].
After the incubation of erythrocytes in-
fected with D6 or FCR3 P.f. strains and isotope-
labelled [10-3H]-6 or [15-3H]-7b, radioactiv-
ity was detected in protein fractions originated 
from the parasite [131]. After treatment with 
EtSH or 8 M urea it was concluded that pro-
teins and isotopically labelled fragments of 
6 and 7b are covalently bonded. No radioac-
tivity was detected after the incubation with 
nonifected erythrocytes or with radiolebeled 
deoxo-ART. Some of alkylated proteins were P. 
falciparum membrane proteins MSA-1, MSA-
2, CRA.5.1, TCTP (Translationally Controlled 
Tumour Protein) and histidine-enriched protein 
(42 kDa) [132, 133]. TCTP possesses bonded 
haem and to some extent is present in the food 
vacuole (FV) membrane. Compound 6 reacted 
in vitro with recombined TCTP in the presence 
of in situ generated haem and formed covalent 
adduct in a 1:1 ratio. The amount of covalent 
adduct decreased to 60% when one of the cys-
teines was chemically blocked. 
A second proposed target was raised upon 
results of very important research [134] that 
ART is a very effective inhibitor of sarco/endo-
plasmic reticulum calcium-dependent ATPase 
(SERCA) orthologous (P. falciparum ATP6) 
and that a catalytic amount of Fe(II) enhanced 
the inhibitory activity of ART. It was evidenced 
that the possible site of action of ART could 
be outside the FV, and that the trigger for ART 
toxicity towards the parasite could be Fe(II) 
situated in the cytosol and not necessarily the 
free haem within the FV. In vitro resistance of 
530 P. falciparum isolates from three coun-
tries (Cambodia, French Guiana and Senegal) 
towards ART and its closest derivatives were 
investigated [10]. It was found that resistance 
was positively correlated only with mutation 
of SERCA P. falciparum ATPase6 genes and 
that P. falciparum ATPase6 is the target of ART 
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Scheme 5. Proposed mechanism of Fe(II) induced decomposition of artemisinin 
and the generation of lethal O- and C-radical species 
antimalarials. All resistant isolates came from 
areas with uncontrolled use of ART derivatives. 
ART and arteether 7b effectively inhibit 
FV proteolytic activity of enzymes that degrade 
haemoglobin, specifically cysteine-protease 
[135]. Compound E-64 (for the structure see 
ref. 136) a specific inhibitor of cysteine-prote-
ase is both an ART and 7b antagonist. These 
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observations further confirmed by ex vivo ex-
periments show accumulation of haemoglobin in 
parasites treated with ART, suggesting the inhi-
bition of haemoglobin degradation. According to 
the above findings, it is not clear how artemisins 
and other peroxides would exert their antima-
larial activity after reaction with free haem in the 
FV, where they inhibit catabolism of haemoglo-
bin and the liberation of haem. 
Recently [137], it was found that artemis-
inin, sodium artesunate and dihydroartemisinin 
react with haemoglobin (ferrous haem), but not 
with methaemoglobin (ferric haem) under stan-
dard solution conditions (50 mM phosphate buf-
fer, pH 7, 37 ºC). The authors claim that the re-
action selectively occurs at the haem sites and 
consists of the progressive, slow decay of the 
Soret band because of haem alkylation and sub-
sequent loss of π-electron delocalization. This 
finding further complicates the elucidation the 
mechanism of action of artemisinins.
Antimalarial activity does not necessarily 
correlate with chemical reactivity. Amino arte-
misinins 28a and 28b react readily with haem to 
give the expected products, but derivatives 3 and 
168 (Figure 28) did not [45,138]. On the con-
trary, derivative 3 reacted with aqueous Fe(II) 
but 168, 28a and 28b were inert [45, 139]. Very 
interesting information came from the discovery 
that compounds such as 169 – 172, which cannot 
generate either primary or secondary C-radicals, 
exhibit pronounced antimalarial activity [125]. 
Similar to 3, artemisone 28e readily reacted with 
aqueous Fe(II) affording corresponding products 
[139]. Both compounds reacted with Fe(OAc)
2
, 
and in the presence of radical trapper 4-oxo-
TEMPO, gave corresponding covalent adducts 
(3% for 3, 10% for 28e and 73% for 173). DFO, 
an iron chelator, antagonized the antimalarial 
activity of aqueous Fe(II)-susceptible artesunate 
and trioxane 3, but had no observable effect on 
aqueous Fe(II)-resistant derivative 168, nor on 
artemisone 28e [139]. It was found that 28e ef-
ficiently alkylates haem [140]. 
Due to high specificity of ARTs for malaria 
parasite SERCA ATPase, and the inhibition of 
SERCA orthologues of P. falciparum (PfATP6) 
and P. vivax (PvSERCA) [134], it was found that 
artemisone 28e is an even better inhibitor, having 
a K
i
 =1.7 ± 0.6 nM for PfATP6, and a K
i
 = 0.072 
Fig. 27. Structures of covalent adducts 163–167 derived from C-centered radicals
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± 0.012 nM for PvSERCA. For comparison with 
ART: K
i
 = 169 ± 31 nM for PfATP6 and K
i
 = 7.7 
± 4.9 nM for PvSERCA [46]. In contrast to these 
derivatives, compound 168 has low inhibitory ac-
tivity against PfATP6 (K
i
 = 277 ± 39 nM), which 
is in contrast to its high in vitro potency (IC
50
 3D7 
= 1.44 nM) [139]. 
Studies with conjugates 173–175 of ART 
derivatives, ozonides and 1,2,4,5-tetraoxanes 
with acridine and nitrobenzyldiazole (NBD) 
fluorochromes (Figure 29) showed that they 
accumulate only in infected erythrocytes, both 
within the cytoplasm and the FV of the para-
site [91, 141]. Formation of the stabile adducts 
of acridine and NBD tagged peroxides with 
biomolecules within parasite was inhibited 
by co-incubation with the iron chelator DFO. 
In addition, the investigated peroxides and 
their conjugates showed marked antagonism 
in combination with iron chelators DFO and 
DFP [141]. All investigated conjugates showed 
high in vitro antimalarial activity in the 5–13 
Fig. 28. Structures and antimalarial activities of derivatives 3, 168–173
and selected derivatives of 28
Fig. 29. Structures of conjugates 173–175
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nM range against the 3D7 P. falciparum strain. 
These results suggest that both the cytoplasm 
and FV of the parasite could be equally pos-
sible sites of action of antimalarial peroxides, 
and that the haem from FV or chelatable ”free” 
iron from the cytoplasm both could trigger the 
scission of the peroxide bond.
Adamantyl peroxide-ozonides OZ277, 
OZ439 and 177, tetraoxane 176 and 1,2,4-tri-
oxane 178 (Figure 30) were subjected to reac-
tion with different ferrous salts. It was shown 
that OZ439 [76] and tetraoxane 176 [91] 
showed significant stability under the applied 
reaction conditions, while OZ277 [76] and tri-
oxanes 177 and 178 readily reacted and formed 
secondary carbon radicals that were intercepted 
with TEMPO [142].
Ozonide OZ277 inhibits PfATP6 with low-
er potency in comparison to ART – K
i
 (OZ277) 
= 7.7 mM vs K
i
 (ART) = 79 nM, and thus sug-
gests that these two peroxides may have different 
mechanisms of action [143]. However, the two 
Fig. 30. Structures of peroxides OZ277, OZ439 and 176–178
compounds have certain similarities like abroga-
tion of the activity of OZ277 in the presence of 
DFO, antagonism in combination with DFO [143] 
and formation of C-centred radicals during reac-
tion with Fe(II), and the formation of the corre-
sponding adduct with TEMPO [65]. Fluorescent 
derivate of OZ277 was localized in the parasite 
cytosol in one parasite and in the FV in the other. 
In the cytosol it was associated with the parasite 
endoplasmatic reticulum. In addition, the ozonide 
OZ277 showed antagonism in combination with 
artesunate.
Based on the finding that the in vitro antima-
larial activity of artemisinin was significantly in-
creased under a 2 % carbon monoxide atmosphere 
(by 40–50 %) and under 20 % oxygen atmosphere 
(by 20–30 %) [144], a detailed study of the inter-
action of artemisone and related derivatives with 
various forms of haemoglobin (Hb), haem, as well 
as an analysis of their antimalarial activities was 
performed [145]. In contrast to ART, artemisone 
does not react with Hb-Fe(II) and oxyHb-Fe(II) to 
produce metHb-Fe(III); in addition, it was shown 
that both artemisinin and artemisone (and 28a, 28b, 
168) are inactive toward Hb-Fe(II) in a 2% carbon 
monoxide atmosphere. On the other hand, both 
compounds induced the oxidation of the haemo-
globin catabolic product, haem-Fe(II), to produce 
haem-Fe(III). In addition, on exposure of haem-
Fe(II) and Hb-Fe(II) to carbon monoxide, stable 
complexes were formed, which are also inactive for 
reactions with peroxide antimalarials. However, in a 
biologically relevant experiment, both compounds 
showed increased antimalarial activity against P. 
falciparum W2 strain under a 2% carbon monox-
ide atmosphere, while the activity of CQ remained 
unchanged. The authors suggested [145] that perox-
ide antimalarials behave as reactive oxygen species 
(ROS), or that they produce ROS via Haber-Weiss 
chemistry. Furthermore, it was concluded that pas-
sivation of haem-Fe(II) by its conversion into the 
CO complex results in decreased decomposition 
of artemisinins (artemisone included), thus making 
them more available for reaction with their actual 
target. The authors proposed that Fe(II), regardless 
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of its origin (Hb-Fe(II) or haem-Fe(II)), is not the 
sole initiator of O–O scission, and suggested that 
another one should be searched for [145].
A three-dimensional QSAR pharmaco-
phore model of the antimalarial activity of bis-
steroidal and mixed steroidal 1,2,4,5-tetraoxanes 
was developed [146]. The model contains two 
hydrogen bond acceptors (lipid) and one hydro-
phobic (aliphatic) feature, and maps well onto the 
potent analogues and many other active peroxide 
antimalarials such as ART, arteether, artesunic 
acid, and simpler tetraoxanes. It appears that the 
presence of at least one hydrogen bond acceptor 
in the trioxane or the tetraoxane moiety is neces-
sary for good activity for this class of compounds. 
Docking calculations with haem suggested that 
the proximity of the Fe(II) and oxygen atom of 
the trioxane or the tetraoxane moiety favours po-
tent activity of the compounds and that electron 
transfer from the peroxide oxygen is crucial for 
mechanism of action. 
Similarly to artemisinins, results from in-
vestigation of tetraoxane’s mechanism of action 
are also contradictory. Reaction of tetraoxane 
179 with Fe2+ in the presence of spin-trap reagent 
TEMPO (a C-radical trapper) gave covalent ad-
ducts 180 and 181 (Figure 31) which confirmed 
C-radicals as interemediers during the process 
[147] same as it happened with ART. The same 
results were obtained with lipophilic tetraoxane 
184, and with more polar and water soluble 106 
(RKA182), independent from using ferrous salts 
or solvents. In addition, during reaction of these 
tetraoxanes with haem, covalent adduct 185 was 
isolated, confirming the alkylation capability of 
tetraoxanes. It is interesting that the same type of 
adduct was isolated no matter which tetraoxane 
was used, obviously due to more stable radicals as 
dominant intermediates. In the same study, during 
Fe2+ induced cleavage of tetraoxanes in the pres-
ence of 2-linoleoyl-1-palmitoyl-sn-phosphatidyl-
choline (PC), observed peroxidation of PC was 
observed, which confirmed an ROS generating 
characteristic for Fenton chemistry.
Differences between 1,2,4,5-tetraoxanes 
and the other peroxides were underlined with the 
studies of the mechanism of action of bis- and 
mixed steroidal tetraoxanes [101]. Performing 
experiments under the same conditions as for 
other antimalarial active peroxides, including 
Fig. 31. Fe(II)-mediated degradation of tetraoxane 179
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those presented above [147], steroidal tetraoxanes 
unexpectedly generated only oxygen centred radi-
cals that did not further rearrange to carbon cen-
tred radicals. When using DMPO and DEPMPO, 
both O- and C-radical traps, the EPR experiments 
revealed only DMPO-•OR and DEPMPO-•OR 
spin-trapped adducts. The corresponding ketones 
were isolated as the only organic products from 
the reaction mixture and no traces of rearranged 
products that would result from C-radical inter-
mediates were detected. Indirect evidence of ex-
isting high valent Fe(IV)=O species was obtained 
from HMDB → HMB rearrangement. Based on 
the evidence two pathways (Scheme 6) were pro-
posed suggesting that tetraoxane peroxides serve 
as the RO• radical source, as well as the source 
of the Fe(IV)=O species. RO• radical species are 
capable of membrane hydroperoxidation (RBC 
membrane, parasite membrane, cytosol, or FV) 
or possibly attack other vital biomolecules. Sup-
port for this observation was given in the study 
of Kumura et al. [148], who reported sharp dif-
ferences in reactivity between tetraoxanes and 
ART during Fe2+ induced oxidative degradation 
of phospholipid PC. While ART were unreactive 
under the applied conditions, tetraoxanes (both 
water soluble and lipophilic derivatives) were 
highly active, and yielded products of oxidation 
of PC even under inert reaction conditions. These 
results confirmed the existence of ROS, O-centred 
radicals and/or Fe(IV)=O, suggested in the study 
with steroidal tetraoxanes [101]. The same prod-
ucts were observed from reaction of PC with Fe2+ 
under O
2
 atmosphere. Furthermore, O’Neill [147] 
and Kumura [148] observed the same product of 
peroxidation of PC. Since in both studies, experi-
ments were performed under inert atmosphere, 
it is concluded that ROS, which reacts with PC, 
could originate only from tetraoxanes. 
Very recently, a non iron-mediated mech-
anism of bioactivation has been proposed by 
Haynes and Monti [149]. Methylene blue (MB) 
was the first synthetic drug ever used in humans, 
and it was Paul Erlich who cured two patients from 
malaria using MB in 1891 [150]. The discovery 
that ART and artemether exhibit synergic effects 
with methylene blue [151], unlike chloroamino-
quinolines, initiated systematic examination of 
reactivity relationship between the drugs with 
the aim to possibly correlate their mechanism 
Scheme 6. Proposed mechanism of action of tetraoxanes
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of antimalarial action. Subsequent research by 
the same group [152] revealed that MB is a 
redox-cycling agent that produces H
2
O
2
 at the 
expense of O
2
 and of NADPH in each cycle 
(Figure 32). Thus, MB consumes the NADPH 
and O
2
 needed for the pathogen’s metabolism, 
very probably seriously affecting the NADPH/
NADP ratio.
The results of subsequent research re-
vealed that artemisone, other artemisinins 
[149] and other peroxide antimalarials like 
ozonides and tetraoxanes [153] are active in 
the presence of MB-ascorbic acid, MB-N-ben-
zyl-1,4-dihydronicotinamide (BNAH), ribo-
flavin–BNAH and riboflavin–NADPH sys-
tems, and yield identical products as those that 
were isolated from the reaction of same the an-
timalarials with Fe(II). According to this pro-
posal, antimalarial peroxides act as oxidants, 
re-oxidizing LMB and FADH2, and so contrib-
ute to the depletion of NADPH (Scheme 7).
Fig. 32. Redox-cycling interconversion between methylene blue (MB) and leucomethylene blue (LMB)
Scheme 7. Biomimetic catalytic system under physiological conditions: works with other flavins, all examined 
artemisinins, tetraoxane, and trioxolane antimalarials
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11. CONCLUSION
Synthetic and semi-synthetic peroxides 
are effective drugs and are used with success 
in the treatment of severe malaria. They are es-
pecially efficient against CQR strains of P. fal-
ciparum, the cause of cerebral malaria. Acces-
sibility, relatively inexpensive preparation, and 
the stability of the 1,2,4-trioxane and 1,2,4,5-te-
traoxane groups to a broad spectrum of reaction 
conditions enables the syntheses of derivatives 
of diverse structures and makes possible the 
discovery of even more effective drug(s). All 
authors emphasized the low toxicity of these 
compounds with rare cases of unwanted side 
effects. To date, there are no major examples 
of appearance of resistance of Plasmodium 
species, except in cases when drugs were used 
without proper control. These facts, together 
with the possibility for combination with other 
non-peroxide drugs, chiefly aminoquinolines, 
opens unrestricted possibilities in combating 
malaria.
The reported results concerning the 
mechanism of antimalarial peroxide action are 
contradictory at first glance. However, having 
in mind that the compounds significantly dif-
fer in their structures that are responsible for 
different logP, bioavailability, passage through 
cellular membranes, and stereospecific inter-
actions with assumed receptors or trigger spe-
cies, the observed differences are logical. Our 
opinion is that antimalarial peroxides may 
themselves have different action pathways and 
that they may have different targets. The above-
mentioned does not exclude certain common 
behaviours, such as the capability of acting as 
alkylating agents. In addition, this does not ex-
clude the possibility that one compound is ac-
tive against several different targets simultane-
ously. Perhaps it should not be expected that all 
peroxides fit into unique mechanism of action. 
It is more likely that they have complex, multi-
targeted mechanisms, including the oxidative 
stress [139].
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